Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405492 | 0.76 | DRD2 (0.37) | — | |
| SCHEMBL1569825 | 0.76 | HRH3 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL2738325 | 0.75 | HRH3 (0.36) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL104775 | 0.75 | HRH3 (0.43) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL24789555 | 0.74 | CHRNA7 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL24734655 | 0.74 | CHRNA7 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL24733191 | 0.74 | CHRNA7 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL475277 | 0.74 | — | — | |
| SCHEMBL24733229 | 0.74 | CHRNA7 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 | |
| SCHEMBL27322457 | 0.73 | HRH3 (0.39) | HRH3KCNH2CYP2D6ALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | HRH3 43/4885KCNH2 48/4885CYP2D6 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.